Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Ganaplacide/Lumefantrine with CYP and Transporter Substrates
NCT05236530Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ganaplacide in malaria (2 cohorts), sponsored by Novartis. Primary endpoints: Observed maximum plasma concentration, Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration and 5 more. Started Mar 2022; status: completed.
02
Drugs
ganaplacide
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05236530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236530.